Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1, 3-4, 8, 16, 18, 22, 25-26, 28, 32, 35-36, 38, 40-43 and 47 are pending in this application.
Response to Amendment
2. Applicant’s amendment filed 08/20/2026 in response to the previous Office Action (05/22/2026) is acknowledged. Rejection of claims 1, 3-4, 18, 22, 25-26, 28, 32, 36, 38, 40-43 and 47 under 35 U.S.C. 102(a)(1) (item 4) and 35 U.S.C. 112(b) (items 6a-6c) has been obviated.
Election/Restrictions
3. Applicant’s election without traverse of Group I and a single disclosed species of compound C1a in the reply filed on 05/08/2026 is acknowledged.
PNG
media_image1.png
400
655
media_image1.png
Greyscale
Previously, the examiner found a prior art and the search was stopped. Now after the response of the First Action, the search for applicant’s invention continued and stopped when a prior art was found.
Note that for the purpose of the search, the definition of “R4 and R5 as alkyl, aryl, arylalkyl, cycloalkyl and haloalkyl” is taken as unsubstituted. If applicant’s intention is unsubstituted alkyl, unsubstituted aryl, unsubstituted arylalkyl, unsubstituted cycloalkyl and unsubstituted haloalkyl, they have to amend the claims so that the record is clear.
Claim Rejections - 35 USC § 102
4. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
6. Claims 1, 3, 16, 18 and 22 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Andersen et al. WO-2004/089470 A2. Cited reference disclose the following three antidiabetic compounds that are the same as applicants when applicants Formula I has the following substituents: R1 = H; R2 = -CONR4R5 wherein R4 and R5 together with the nitrogen atom to which they are attached form unsubstituted or alkyl substituted heterocyclic ring; R3 = H or alkyl; X1 = H or alkyl; W = -NH-SO2- or -SO2-NH-;; m = 0; and k = 0 or 1.
PNG
media_image2.png
461
1331
media_image2.png
Greyscale
PNG
media_image3.png
645
1465
media_image3.png
Greyscale
PNG
media_image4.png
332
824
media_image4.png
Greyscale
Since said compounds are the same as applicants, a 102(a)(1) rejection is proper.
Objection
7. Claims 4, 8, 25-26, 28, 32, 35-36, 38, 40-43 and 47 are objected to as being dependent upon a rejected base claim, but may be allowable after further search if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Conclusion
8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kahsay Habte Ph.D. whose telephone number is (571)272-0667. The examiner can normally be reached on 8:30 - 5:00 PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JEFFREY MURRAY can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/Kahsay Habte/
Primary Examiner, Art Unit 1624
September 1, 2026
Prosecution Insights